cliot (version 1.0.0)

asymptomatic_myeloma_prognosis: Mayo Clinic Risk Stratification for Smoldering Multiple Myeloma (20-2-20 Model)

Description

Calculates the risk stratification for patients with Smoldering Multiple Myeloma (SMM) using the "20-2-20" criteria developed by the Mayo Clinic. This model predicts the risk of progression to active Multiple Myeloma (MM) based on three risk factors: Bone Marrow Plasma Cells (BMPC) > 20%, Serum M-protein > 2 g/dL, and Serum Free Light Chain (FLC) ratio > 20.

Usage

asymptomatic_myeloma_prognosis(bmpc_percent, m_protein_g_dl, flc_ratio)

Value

A list containing:

Total_Risk_Factors

The count of risk factors present (0, 1, 2, or 3).

Risk_Group

Classification (Low, Intermediate, or High Risk).

Median_Time_to_Progression

Estimated median time to progression to active myeloma.

Progression_Risk_2yr

Estimated probability of progression within 2 years.

Arguments

bmpc_percent

Numeric. Bone marrow plasma cells in percentage. (Threshold: > 20%).

m_protein_g_dl

Numeric. Serum M-protein level in g/dL. (Threshold: > 2 g/dL).

flc_ratio

Numeric. Serum Free Light Chain ratio (involved : uninvolved). (Threshold: > 20).

References

Lakshman A, Rajkumar SV, Buadi FK, et al. Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. Blood Cancer J. 2018;8(6):59. doi:10.1038/s41408-018-0077-4

Examples

# Example 1: High Risk (2 factors)
# BMPC 30%, M-protein 1.5, FLC Ratio 25
asymptomatic_myeloma_prognosis(30, 1.5, 25)

# Example 2: Low Risk (0 factors)
# BMPC 10%, M-protein 1.0, FLC Ratio 8
asymptomatic_myeloma_prognosis(10, 1.0, 8)